Covid-19 roundup: Mod­er­na posts $1.1B in Covid-19 vac­cine de­posits; Gilead CEO sees po­ten­tial need for Vek­lury on a 'sea­son­al ba­sis'

Mod­er­na’s $MR­NA ex­ec­u­tive team is clear­ly itch­ing to get a near-term EUA for their Covid-19 vac­cine.

The mR­NA wun­derkind post­ed an up­date on their piv­otal tri­al for mR­NA-1273, with a note that they have $1.1 bil­lion in cus­tomer de­posits for the vac­cine.

Right now Mod­er­na CEO Stéphane Ban­cel and his team are neck-and-neck with Pfiz­er/BioN­Tech in a race to un­veil da­ta on what could be the first vac­cines for the pan­dem­ic. And he is not one to down­play the com­pa­ny’s prospects.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER